ClinicalTrials.gg
TerminatedNCT01753102Updated Oct 9, 2018

Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

A Phase 3 interventional study of Estradiol in Vulvar Atrophy and Vaginal Atrophy, sponsored by Sun Pharmaceutical Industries Limited. Terminated at 1 site in India. Open to female participants. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment

Why this study was terminated
Slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Sex
Female
01

Study summary

Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing 17ß-estradiol.

The estradiol in estradiol vaginal tablet is chemically and biologically identical to the endogenous human estradiol and is therefore classified as a human estrogen.

The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem®)which is approved and marketed in the US.

Read the detailed description

Estradiol vaginal tablet is indicated for use in the treatment of symptoms of atrophic vaginitis due to estrogen deficiency.

This is a randomized, observer blind, parallel groups, active and placebo controlled study to test the clinical endpoint bioequivalence of test product (Estradiol vaginal tablet, 10mcg of Sun Pharmaceutical Industries Ltd. India) relative to reference (Vagifem®, Estradiol vaginal tablet, 10mcg estradiol of Novo Nordisk) in treatment of vulvar and vaginal atrophy.

The patients will be administered with one tablet intravaginally daily for 14 days.

02

Conditions studied

  • Vulvar Atrophy
  • Vaginal Atrophy

Keywords

  • Estradiol
  • Vulvar atrophy
  • vaginal atrophy
03

In context

Lead sponsor

Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • woman
  • At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal atrophy
  • ≤ 5% superficial cells on vaginal smear cytology
  • Vaginal pH > 5.0

Exclusion criteria

Exclusion Criteria:

  • Consumption of estrogen alone or estrogen/progestin containing drug products.
  • Allergy to estradiol or related products
  • History of breast cancer and significant risk factors for endometrial cancer
  • Abnormal genital bleeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Estradiol

    Intravaginal self-administration of study medication once daily for 14 days.

    Drug: Estradiol

  • Active comparator
    Reference: Estradiol

    Intravaginal self-administration of study medication once daily for 14 days.

    Drug: Estradiol

  • Placebo comparator
    Placebo

    Intravaginal self-administration of study medication once daily for 14 days.

    Drug: Estradiol

Interventions

  • one tablet will be inserted daily for 14 days

    Also known as: Vagifem

06

What researchers measure

Primary outcomes

  1. Vaginal pH

    Time frame: 14 days

Secondary outcomes

  1. Symptoms of vulvar and vaginal atrophy

    Each subject will specify identified most bothersome symptoms vaginal dryness, vaginal and/or vulvar irritation/ itching, dysuria, vaginal pain associated with sexual activity, vaginal bleeding associated with sexual activity) and self-evaluate the symptom on a pre-defined scale

    Time frame: 14 days

07

Study locations

1 site
  • Biniwale Clinic Pvt. Ltd,
    Pune, Maharashtra 411004, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Apr 2013, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2012
First posted
Dec 20, 2012
StartActual
Nov 6, 2012
Primary completionActual
Apr 30, 2013
CompletionActual
Apr 30, 2013
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01753102
Responsible party
Sponsor
First posted
Dec 20, 2012
Start date
Nov 6, 2012
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013
Last update
Oct 9, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion